We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+3.36%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$19.1M
AUM Growth
-$25.8M
Cap. Flow
-$24.9M
Cap. Flow %
-130.36%
Top 10 Hldgs %
74.76%
Holding
25
New
–
Increased
4
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
BNTC icon
Benitec Biopharma
BNTC
+$248K
2
IRON icon
Disc Medicine
IRON
+$168K
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$151K
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$123K

Top Sells

Rank Stock Value
1
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.22M
2
INSM icon
Insmed
INSM
+$1.12M
3
MIST icon
Milestone Pharmaceuticals
MIST
+$1.08M
4
BHVN icon
Biohaven
BHVN
+$593K
5
GERN icon
Geron
GERN
+$519K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Communication Services 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.1B
$2.53M 13.27%
36,700
-15,500
-30% -$1.12M
MIST icon
2
Milestone Pharmaceuticals
MIST
$148M
$2.42M 12.68%
1,025,806
-628,348
-38% -$1.08M
GERN icon
3
Geron
GERN
$924M
$1.77M 9.27%
500,000
-130,000
-21% -$519K
ARDX icon
4
Ardelyx
ARDX
$1.25B
$1.7M 8.9%
335,400
-34,600
-9% -$191K
FENC icon
5
Fennec Pharmaceuticals
FENC
$355M
$1.24M 6.48%
195,700
-19,300
-9% -$98.9K
BBIO icon
6
BridgeBio Pharma
BBIO
$16.7B
$1.11M 5.79%
40,300
-8,700
-18% -$225K
MLYS icon
7
Mineralys Therapeutics
MLYS
$2.38B
$972K 5.09%
79,000
– –
KNSA icon
8
Kiniksa Pharmaceuticals
KNSA
$4.85B
$908K 4.75%
45,900
-15,500
-25% -$354K
BHVN icon
9
Biohaven
BHVN
$2.14B
$848K 4.44%
22,700
-12,700
-36% -$593K
BNTC icon
10
Benitec Biopharma
BNTC
$401M
$783K 4.1%
62,000
+23,000
+59% +$248K
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$1.84B
$727K 3.81%
55,000
+8,800
+19% +$151K
JSPR icon
12
Jasper Therapeutics
JSPR
$23.8M
$684K 3.58%
32,000
– –
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$673K 3.52%
64,000
– –
IRON icon
14
Disc Medicine
IRON
$2.88B
$672K 3.52%
10,600
+2,900
+38% +$168K
BLUE
15
DELISTED
bluebird bio
BLUE
$658K 3.45%
78,912
-1
-0% -$9
ARQT icon
16
Arcutis Biotherapeutics
ARQT
$3.43B
$645K 3.38%
46,300
+11,200
+32% +$123K
RGNX icon
17
Regenxbio
RGNX
$628M
$446K 2.34%
57,750
– –
MCRB icon
18
Seres Therapeutics
MCRB
$49.7M
$283K 1.48%
17,038
– –
SPRB
19
Spruce Biosciences
SPRB
$119M
$31.5K 0.16%
1,000
– –
GOOG icon
20
Alphabet (Google) Class C
GOOG
$3.91T
– –
-100
Closed -$16.7K
IWM icon
21
PUT
iShares Russell 2000 ETF
IWM
$81.6B
– –
-82,500
Closed -$18.2M
MIRM icon
22
PUT
Mirum Pharmaceuticals
MIRM
$6.87B
– –
-45,000
Closed -$1.75M
MSFT icon
23
Microsoft
MSFT
$2.86T
– –
-100
Closed -$43K
LUMO
24
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-39,589
Closed -$153K
MRNS
25
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-693,778
Closed -$1.22M

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
PA
Prossimo Advisors San Luis Obispo, California $16.4M AUM 14% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return

Lion Point Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Lion Point Capital held 25 positions worth $19.1M, down 57% from $44.9M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Lion Point Capital withdrew a net $24.9M in Q4 2024, closing 6 positions and reducing 9 holdings. Its most notable exit was Marinus Pharmaceuticals, Inc, an estimated $1.22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 53% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Lion Point Capital added an estimated $248K to Benitec Biopharma.

  • Lion Point Capital added most to Benitec Biopharma in Q4 2024, an estimated $248K increase.
  • Lion Point Capital's biggest Q4 2024 reduction was Insmed, cutting an estimated $1.12M.
  • Lion Point Capital fully exited Marinus Pharmaceuticals, Inc in Q4 2024, selling an estimated $1.22M.
  • Lion Point Capital's ten largest holdings make up 75% of its $19.1M portfolio in Q4 2024.
  • Lion Point Capital opened 0 new positions and closed 6 in Q4 2024.
  • Lion Point Capital's portfolio value fell 57% quarter-over-quarter to $19.1M.

Based on Lion Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.